相关临床试验
1144
157 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1966
进行中（未招募）
3
0.3%
已完成
653
57.1%
尚未招募
154
13.5%
招募中
304
26.6%
暂停
1
0.1%
Unknown
1
0.1%
撤回
28
2.5%
暂无批准数据
- Bayer and Vanderbilt University Medical Center announced a strategic five-year collaboration agreement to advance innovative therapies from target identification through Investigational New Drug application. - The partnership will initially focus on cardiovascular and kidney diseases, two therapeutic areas with significant unmet medical need, while spanning across all indications currently pursued by Bayer. - The collaboration will leverage VUMC's comprehensive datasets, including the BioVU collection of DNA and plasma, to enable data-driven insights and accelerate drug discovery and development. - The agreement combines Bayer's expertise in drug discovery and translational sciences with VUMC's deep preclinical and clinical knowledge to advance precision medicine approaches.
- A Vanderbilt study demonstrates that AI-powered interruptive alerts led to 42% suicide risk assessment completion rate compared to 4% with passive alerts in neurology clinics. - The VSAIL model analyzes electronic health records to identify high-risk patients, flagging only 8% of total visits for targeted screening, making implementation feasible in busy clinical settings. - Research validates the system's efficiency in neurology clinics, where certain conditions correlate with increased suicide risk, with no reported adverse events during the 30-day follow-up period.
